Weiss Valuation: Where Does AMGN Stand Today?
At 2.95%, AMGN's current yield sits near the midpoint of its 10-year historical range (2.77%–3.66%), with a historical median of 3.27%. The Weiss model rates this as fair value — neither a compelling entry nor a reason to sell an existing position.
The undervalued price threshold — the level at which AMGN historically becomes an attractive buy — currently sits at $264.03. The overvalued threshold, above which the stock is historically expensive, is $348.82. The current price of $326.98 places the stock between the two bands, in the fair value zone.
Dividend Quality Assessment
Amgen Inc. scores 59/100 on DividendVisual's quality scale — an Average rating. The dividend is likely safe but warrants closer scrutiny on payout coverage. Key metrics: a 67% payout ratio, the dividend consumes 73% of free cash flow, growing at 8.3% annually over the past 5 years.
Amgen Inc. has maintained its dividend without a cut for 9 years, establishing a meaningful income track record.
The current payout ratio is 67% — a moderate level. The dividend is well-covered but investors should monitor any trend toward higher payout.
10-Year Yield History
Over the past decade, Amgen Inc.'s dividend yield has ranged from a low of 2.77% (when the stock was most expensive relative to its dividend) to a high of 3.66% (when it was most attractively priced). The historical median yield — a reasonable proxy for fair value — is 3.27%.
Investors who consistently bought AMGN near its historical yield maximum and held for 3–5 years have, historically, earned both above-average income and above-average capital appreciation as the yield mean-reverted toward the median. This is the core logic of yield-based valuation: price and yield are inversely related, so buying high yield means buying low price.
Income Projection: What AMGN Could Generate
A $10,000 investment at the current price and yield would generate approximately $295 in year-one income. With dividends reinvested and a 8.3% annual growth rate maintained, that same investment would produce roughly $1,033 per year in income by year 10 — a yield on cost of 10.3%.
These projections assume no share price appreciation — only the compounding effect of reinvested dividends at a constant price. In practice, share price changes will affect the total return. The projection is intended to illustrate the power of dividend reinvestment over time, not to predict a specific outcome.
Key Risks to Consider
Amgen Inc.'s dividend appears well-supported by current earnings and cash flow. No material red flags are flagged by the quality model, though macro risks (rising rates, sector disruption) always apply.
Beyond company-specific factors, all dividend stocks carry interest rate risk: when rates rise, income investors have alternatives, and dividend stock valuations tend to compress. Amgen Inc.'s position in the Healthcare sectorshould be evaluated in the context of your portfolio's overall rate sensitivity.
Bottom Line
Amgen Inc. is trading at fair value by the Weiss method — neither a bargain nor overpriced. Income investors already holding the stock can continue to do so comfortably. Those looking to initiate a position might consider waiting for a dip toward the undervalued band, or beginning a partial position now and adding on weakness.